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1010-135 Clopidogrel Increases Post Cardiac Surgery Bleeding 
Only if Given Within Three Days of Surgery
Rashed S. Bakri, Ali A. Haydar, Nabil M. Hujairi, Antoine Abche, David J. Goldsmith, 
American University of Beirut, Beirut, Lebanon, Guy's Hospital, London, United Kingdom
Background: 
Clopidogrel (CL) in addition to aspirin is now standard care for treatment of acute coro-
nary syndromes and for coronary stent thrombosis prevention. If this fails and patients
need coronary artery bypass grafting (CABG), the irreversible effect of clopidogrel on
platelet function is a concern. This study aimed to evaluate the role of preoperative use of
CL in bleeding after CABG.
Methods: 
A total of 462 patients who underwent CABG in a single surgical centre in 2001-2003
were studied. Patients exposed to CL within 3 days (n=67) (group A), between 3 and 7
days (n=34) (group B), and people not taking CL (n=361) (group C) prior to surgery were
all compared. Bleeding index (BI), a modified TIMI criterion, which is a composite of drop
in hemoglobin and number of blood units transfused after surgery, was the primary out-
come measured. Mortality, acute myocardial infarction, and re-exploration for bleeding
were the secondary outcomes.
Results: 
Our data showed that group A have a higher mean BI and more TIMI major bleeding
(BI>5 g/dl) than either group B or C (p=0.009 and 0.03 respectively for inter-groups com-
parison). There were no differences in the secondary outcomes occurrence among the
three groups. See table.
Conclusion: In this largest-to-date study we have shown that clopidogrel increased the
risk of major post-CABG bleeding only if taken within three days of surgery. This has
major implications for future use of clopidogrel.
*Inter-groups comparison
† Groups A and C comparison
‡ Groups B and C comparison
1010-136 Torsional Deformation in Ischemic and Remote Left 
Ventricular Regions During Acute Circumflex and 
Anterior Descending Coronary Occlusion
Filiberto Rodriguez, Tomasz A. Timek, Frank Langer, David Liang, George T. Daughters, 
Neil B. Ingels, Jr., D. Craig Miller, Stanford University, Stanford, CA, Palo Alto Medical 
Foundation, Palo Alto, CA
Background: Contraction of helically oriented fibers in the left ventricle (LV) results in
systolic torsion, reducing transmural fiber strain gradients and oxygen demand. Acute
ischemia decreases torsion in the ischemic region, but effects in remote regions are
unknown. We investigated alterations in local and remote LV torsional deformation during
acute ischemia in two different territories.
Methods: Six sheep had radiopaque markers implanted on the LV to measure fractional
area shrinkage (FAS = 100•(regional areamax – regional areamin)/regional areamax) and
maximal regional systolic torsion (Φmax) using biplane videofluoroscopy one week after
surgery, before and during acute anterior wall ischemia (proximal left anterior descending
[LAD] occlusion) or acute posterior wall ischemia (distal left circumflex [LCx] occlusion).
Color Doppler transesophageal echocardiography graded mitral regurgitation (MR).
Results: Acute LAD and distal LCx occlusions caused similar hemodynamic insults
(Table). Acute LAD occlusion decreased septal FAS and anterior Φmax, whereas acute
distal LCx occlusion reduced free wall FAS and posterior Φmax, but interestingly
increased anterior and lateral Φmax.
Conclusion: This paradoxical increase in regional free wall systolic torsion in non-
ischemic sites suggests a compensatory unloading of remote myocardium and highlights
regional differences between various ischemic injuries. Such findings may influence
approaches for ventricular remodeling surgery.
1010-137 Intravascular Ultrasound and Valved Stent for Beating 
Heart Valve Implantation: Is There Really a Need for 
Angiography?
Christoph H. Huber, Bettina Marty, Pierrgiorgio Tozzi, Antonio F. Corno, L.K. von 
Segesser, University Hospital Lausanne, Lausanne, Switzerland
BACKGROUND: We evaluated feasibility of intravascular ultrasound (IVUS) guided off-
pump aortic (AVR) and pulmonary valve implantation (PVR) using a new self-expanding
Valved Stent without angiography.
METHODS: Six pigs (62.5±8.7 Kg) underwent either off-pump A) AVR (n=3) or B) PVR
(n=3) using a self-expanding Valved Stent. After left sided thoracotomy, purse-string
sutures were placed on either ventricular apex. Under fluoroscopy, a guide wire was
inserted trough the apex and advanced over the A) aortic or B) pulmonary valves respec-
tively. A wire-guided IVUS catheter transducer (6F, 12.5MHZ) was inserted and the origi-
nal A) aortic and B) pulmonary valves identified, the valve diameter and the A) root or B)
trunk length were measured. Target site was identified and marked by needles on the
body surface. After removal of the IVUS, the Valved Stent delivery system was intro-
duced over the guide wire under fluoroscopy and the Valved Stent deployed over the
native valves. Assessment was performed using invasive pressure measurements, IVUS
and intracardiac ultrasound including: leaflet motion, planimetric valve orifice, transvalvu-
lar gradient, regurgitation and paravalvular leaking. Macroscopic analyse was performed
at necropsy.
RESULTS: Both groups showed good valvular function, with full valvular opening and
closing. In B) one paravalvular leak was found due to size mismatch. Coronary flow was
not impaired in A). At necropsy in A) all, in B) two Valved Stent were correctly placed and
safely anchored to the vessel wall.
CONCLUSION: IVUS guided beating heart aortic and pulmonary valve implantation
using a self-expanding Valved Stent is feasible and might eliminate the need for per-pro-
cedural angiography.
1010-138 Prosthetic Endocarditis: Which Therapy for Which 
Patient?
Gilbert H. Habib, Christophe Tribouilloy, Franck Thuny, Amel Brahim, Murielle Amazouz, 
Georges Nadji, Jean-François Avierinos, Jean-Paul Casalta, François Coviaux, Pierre 
Ambrosi, La Timone Hospital, Marseille, France, Hospital Sud, Amiens, France
Background. Prosthetic valve infective endocarditis (PVIE) still carries an unacceptable
mortality risk and the best therapeutic option (medical vs surgical) is still controversial.
Past studies were limited by the small number of pts and gave discordant results.
Objectives: to assess the prognostic markers of outcome and the influence of therapy in
a large series of pts with PVIE
Methods. One hundred and four consecutive pts from 2 centers (65 biological -39
mechanical, 20 early-84 late) fulfilled Duke criteria for PVIE and underwent evaluation
and follow-up. Among them, 34 (33%) were caused by Streptococci, 25 (24%) by Staphy-
lococci, 25 (24%) had negative BC. Major end-points were in hospital and long-term mor-
tality.
Results. 
Among 104 pts, 22 (21%) died in-hospital. Factors associated with death were comorbid-
ity (p=.07), severe regurgitation (p=.006), S aureus infection (p<.001), “complicated”
PVIE (p=.07), and CHF (p<.001). By multivariate analysis, CHF (OR=5.5), and S aureus
(OR =6.1) were the only independent predictors of death.
Fifty-one (49%) pts underwent surgery during the acute phase. For the entire population,
in-hospital mortality was not significantly different in operated and non-operated patients
(17% vs 25% ,p=ns). However, mortality was lower in operated than in non-operated
patients among 25 pts with S aureus PVIE, (27 vs 73%, p=.03) and among 43 pts with
more than one risk factors (31 vs 71%, p=.02).
Among 82 in-hospital survivors, 21 (26%) new deaths occurred during late follow-up. Pre-
Group A
N=67
Group B
N=34
Group C
N=361
P-value
“Bleeding index”g/dl 5.42 ± 2.22 4.39 ± 1.81 4.49 ± 2.05 0.009*
0.002†
0.905‡
Bleeding index more than 5 g/dl 56.7% 38.2% 39.6% 0.03*
0.009†
0.875‡
Mortality 1.5% 5.4% 1.9% 0.342
AMI 1.5% 0% 1.1% 0.776
Re-exploration 1.5% 2.8% 1.6% 0.869
LAD Distal LCx
HEMODYNAMICS preIschemia Ischemia preIschemia Ischemia
HR (min-1) 99±11 107±9 102±12 102±12
LV dP/dtmax (mmHg/sec) 1450±460 1040±292* 1700±433 1140±455*
SV (ml) 44±4 31±4* 44±9 34±5*
LVESP (mmHg) 82±15 63±13* 87±21 75±24*
MR (0-4+ scale) 0.8±0.8 0.9±0.7 0.8±0.8 1.2±1.1
FRACTIONAL AREA SHORTENING
Anteroseptal (%) 19±4 7±2* 22±5 22±6
Posteroseptal (%) 25±4 14±4* 26±4 19±5*
Anterolateral (%) 18±4 16±4 18±5 14±4*
Posterolateral (%) 20±6 21±4 20±4 11±3*
MAXIMAL SYSTOLIC TORSION
Anterior Wall Φmax (degrees) 2.73±3.82 –0.55±3.00* 4.21±3.96 7.09±3.46*
Lateral Wall Φmax (degrees) 5.04±3.37 3.29±2.20 4.94±2.44 7.79±2.66*
Posterior Wall Φmax (degrees) 2.65±4.05 4.82±2.12 2.86±2.85 1.48±2.95*
* p<0.05, ischemia vs. pre-ischemia, t-test for paired observations.  Data expressed as 
Mean±1SD.
